Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ImmunoGen Inc (NASDAQ:IMGN)

4.03
Delayed Data
As of Apr 21
 -0.16 / -3.82%
Today’s Change
1.51
Today|||52-Week Range
9.45
+97.55%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$352.0M

Company Description

ImmunoGen, Inc. is a biotechnology company, which develops novel anticancer therapeutics using its antibody-drug conjugate technology. Its product candidates include Mirvetuximab Soravtansine, Coltuximab ravtansine and Kadcyla . The company was founded in March 1981 and is headquartered in Waltham, MA.

Contact Information

ImmunoGen, Inc.
830 Winter Street
Waltham Massachusetts 02451-1477
P:(781) 895-0600
Investor Relations:

Employees

Shareholders

Other institutional51.04%
Individual stakeholders3.08%
Mutual fund holders25.25%

Top Executives

Mark J. EnyedyPresident, Chief Executive Officer & Director
David B. JohnstonChief Financial Officer & Executive Vice President
Richard J. GregoryChief Scientific Officer & Executive VP
Anna BerkenblitChief Medical Officer & Vice President
John M. LambertExecutive Vice President